LEADER 00000cam 2200637Ki 4500
001 on1079760018
003 OCoLC
005 20181225051927.2
006 m o d
007 cr cnu---unuuu
008 181220s2011 gw a objv 000 0 eng d
020 9783845232188|q(electronic bk.)
020 3845232188|q(electronic bk.)
020 |z9783832965242
020 |z3832965246
035 (OCoLC)1079760018
037 22573/ctv93248z|bJSTOR
040 JSTOR|beng|erda|epn|cJSTOR|dOCLCO
049 CKEA
050 4 K1519.D78|bA75 2011eb
082 04 346.430486|222
100 1 Ahn, Hyewon.
245 10 Patentability of chemical selection inventions :|bthe
Olanzapine and Escitalopram decisions /|cHyewon Ahn.
250 First edition.
264 1 Baden-Baden :|bNomos,|c2011.
300 1 online resource (75 pages) :|billustrations
336 text|btxt|2rdacontent
337 computer|bc|2rdamedia
338 online resource|bcr|2rdacarrier
500 Originally presented as the author's thesis--Universität
München, 2010.
504 Includes bibliographical references (pages 69-75).
588 0 Print version record.
650 0 Drugs|vPatents.
650 0 Patent laws and legislation|vCases.
650 0 Conflict of laws|xPatents|vCases.
650 0 Drug development.
650 0 Olanzapine.
650 2 Citalopram.
650 7 Conflict of laws|xPatents.|2fast|0(OCoLC)fst00874964
650 7 Drug development.|2fast|0(OCoLC)fst00898670
650 7 Drugs.|2fast|0(OCoLC)fst00898761
650 7 Olanzapine.|2fast|0(OCoLC)fst01045171
650 7 Patent laws and legislation.|2fast|0(OCoLC)fst01054823
650 7 Patentfähigkeit.|2gnd
650 7 Enantiomere.|2gnd
650 7 Wirkstoff.|2gnd
650 7 LAW / Commercial / General.|2bisacsh
651 7 Germany.|2idszbz
655 7 Patents.|2fast|0(OCoLC)fst01423842
655 7 Trials, litigation, etc.|2fast|0(OCoLC)fst01423712
776 08 |iPrint version:|aAhn, Hyewon.|tPatentability of chemical
selection inventions.|bFirst edition.|dBaden-Baden : Nomos,
2011|z9783832965242|w(DLC) 2012474049|w(OCoLC)719426677
914 on1079760018
994 92|bCKE
